@article{PAR00011397,
  title = {{A}ntibodies to a single, conserved epitope in {A}nopheles {APN}1 inhibit universal transmission of {P}lasmodium falciparum and {P}lasmodium vivax {M}alaria},
  author = {{A}rmistead, {J}. {S}. and {M}orlais, {I}sabelle and {M}athias, {D}. {K}. and {J}ardim, {J}. {G}. and {J}oy, {J}. and {F}ridman, {A}. and {F}innefrock, {A}. {C}. and {B}agchi, {A}. and {P}lebanski, {M}. and {S}corpio, {D}. {G}. and {C}hurcher, {T}. {S}. and {B}org, {N}. {A}. and {S}attabongkot, {J}. and {D}inglasan, {R}. {R}.},
  editor = {},
  language = {{ENG}},
  abstract = {{M}alaria transmission-blocking vaccines ({TBV}s) represent a promising approach for the elimination and eradication of this disease. {A}n{APN}1 is a lead {TBV} candidate that targets a surface antigen on the midgut of the obligate vector of the {P}lasmodium parasite, the {A}nopheles mosquito. {I}n this study, we demonstrated that antibodies targeting {A}n{APN}1 block transmission of {P}lasmodium falciparum and {P}lasmodium vivax across distantly related anopheline species in countries to which malaria is endemic. {U}sing a biochemical and immunological approach, we determined that the mechanism of action for this phenomenon stems from antibody recognition of a single protective epitope on {A}n{APN}1, which we found to be immunogenic in murine and nonhuman primate models and highly conserved among anophelines. {T}hese data indicate that {A}n{APN}1 meets the established target product profile for {TBV}s and suggest a potential key role for an {A}n{APN}1-based panmalaria {TBV} in the effort to eradicate malaria.},
  keywords = {},
  booktitle = {},
  journal = {{I}nfection and {I}mmunity},
  volume = {82},
  numero = {2},
  pages = {818--829},
  ISSN = {0019-9567},
  year = {2014},
  DOI = {10.1128/iai.01222-13},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00011397},
}